NDAOPHTHALMICGEL
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZIRGAN (ganciclovir) by Bausch + Lomb is dna polymerase inhibitors [moa]. Approved for cytomegalovirus retinitis, cytomegalovirus infections. First approved in 2009.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIRGAN (ganciclovir) is an ophthalmic gel formulation containing a nucleoside analog DNA polymerase inhibitor approved in September 2009 by the FDA. It is indicated for treating cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including those with AIDS, and for CMV disease prevention in adult transplant recipients at risk. The drug works by inhibiting viral DNA polymerase, thereby suppressing CMV replication in ocular tissues.
$0.0BPart D
Mechanism of Action
DNA Polymerase Inhibitors
Pharmacologic Class:
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
Indications (2)
Worked on ZIRGAN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.